Čes. slov. farm. 2008, 57(5):221-224

Effect of montelukast on the treatment of asthma bronchiale in pediatric patients with perennial allergic rhinitis

L. Bartošíková^1,*, J. Nečas¹, T. Bartošík², M. Pavlík², P. Fráňa³, L. Fráňa⁴

¹ Univerzita Palackého Olomouc, Lékařská fakulta, Ústav fyziologie

² Fakultní nemocnice U sv. Anny v Brně, Anesteziologicko-resuscitační klinika

³ Fakultní nemocnice U sv. Anny v Brně, II. Interní klinika

⁴ Alergologická a imunologická ambulance, Velké Meziříčí

Antileukotrienes represent a group of medicaments used in the treatment of bronchial asthma and allergic rhinitis. Montelukast is a drug belonging to the group of medicaments blocking leukotriene receptors (Cys-LT 1 receptor). It is a specific leukotriene receptor antagonist with strong anti-inflammatory effects designed for oral administration. The study monitors the effectiveness and safety of the treatment with montelukast, administered once a day in the evening in 5mg dose, over a 4-month period, to a group of children with the diagnosis of mild persistent bronchial asthma with deterioration of problems after exercise and with perennial allergic rhinitis. The results of the study demonstrate significant positive effects of the preparation used. A significant improvement of FEV1 and PEF values was registered, as well as a statistically significant remission of both day and nocturnal symptoms of the disease and significantly lower consumption of short-acting β₂-sympathomimetics. No adverse effects were observed.

Keywords: antileukotrienes; montelukast; bronchial asthma; allergic rhinitis

Received: July 15, 2008; Accepted: August 20, 2008; Published: May 1, 2008  Show citation